Your Article Summary
See Latest ArticlesA 6-Month, Multicenter, Single-Arm Pilot Study to Evaluate the Efficacy and Safety of Generic Tacrolimus (TacroBell) After Primary Renal Transplantation
Transplantation Proceedings, 07/02/09
Kim SJ et al. - Tacrolimus has been shown to be an important immunosuppressive agent in organ and bone marrow transplantation. Treatment with TacroBell is considered to be efficient and safe after primary renal transplantation.
Related Articles
Association between exposure to topical tacrolimus or pimecrolimus and cancers
Annals of Pharmacotherapy, 11/16/09
Relevance Score: 92%
A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids
Liver Transplantation, 11/03/09
Relevance Score: 89%
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Modern Rheumatology, 10/05/09
Relevance Score: 89%
Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children
Bone Marrow Transplantation, 11/19/09
Relevance Score: 88%
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
Clinical Pharmacology & Therapeutics, 10/29/09
Relevance Score: 87%
Today in Transplantation...keeping you current
Receive free subspecialty "5-minute updates" via email
Arteriovenous fistula in an autotransplanted kidney segment: Successful angiographic management
Scandinavian Journal of Urology and Nephrology, 12/04/09
Indices of systemic atherosclerosis are superior to ultrasound resistance indices for prediction of allograft survival
Nephrology Dialysis Transplantation, 12/04/09
Echocardiographic findings in kidney transplant patients with autosomal dominant polycystic kidney disease
Scandinavian Journal of Urology and Nephrology, 12/04/09